Global GLP-1/GIPR Dual Peptide Agonist Market Strategic Research Report

Scope of the Report

The global GLP-1/GIPR Dual Peptide Agonist market size is predicted to grow from US$ 29,561 million in 2025 to US$ 64,420 million in 2032; it is expected to grow at a CAGR of 11.7% from 2026 to 2032.

In 2025, global GLP-1/GIPR Dual Peptide Agonist production reached approximately 156.36 M Units, with an average global market price of around 193.26 USD per Unit.

A GLP-1/GIPR Dual Peptide Agonist is a single therapeutic agent (usually a peptide) designed to activate both the GLP-1 receptor (GLP-1R) and the GIP receptor (GIPR). By stimulating these two incretin pathways together, it aims to improve metabolic control—typically by enhancing glucose-dependent insulin secretion, reducing glucagon when appropriate, slowing gastric emptying, and decreasing appetite/food intake—so it can support blood-glucose lowering and weight loss in conditions such as type 2 diabetes and obesity.To date, Tirzepatide is the only commercially available GLP-1/GIPR Dual Peptide Agonist product in the world.

GLP-1/GIPR Dual Peptide Agonists are reshaping the incretin field because they tackle a long-standing clinical and commercial pain point in metabolic care: achieving meaningful, sustained weight reduction and cardiometabolic improvement without forcing patients and providers into a tradeoff between efficacy, tolerability, and long-term adherence. By co-activating GLP-1 and GIP pathways in a single molecule, these therapies can deliver a broader metabolic effect than GLP-1 alone—supporting glucose control while driving appetite reduction and weight loss that can translate into improvements across obesity-linked comorbidities—while modern long-acting designs and carefully tuned receptor balance aim to preserve potency with manageable gastrointestinal burden and simpler dosing routines. Industry momentum is being driven by unprecedented demand for effective obesity and diabetes treatments, rising recognition of obesity as a chronic disease with downstream health-system costs, strong payer and employer interest in outcomes that reduce long-term risk, and rapid advances in peptide engineering, formulation, and device delivery that make scalable, patient-friendly products feasible. The market potential remains substantial as dual agonists expand from specialist-driven use toward broader chronic-care adoption, diversify into new formulations and delivery formats, and compete through differentiation on tolerability, durability of effect, and real-world outcomes, positioning the category as a durable growth engine within biopharma’s most strategically important therapeutic area.

The upstream raw materials for GLP-1/GIPR Dual Peptide Agonist mainly include amino acids, condensation reagents, activators, resin carriers, etc. Typical raw material suppliers include Merck, Bachem, AAPPTec, Thermo Fisher, etc. The downstream applications are mainly in the treatment of obesity and diabetes.

The single-line production capacity of GLP-1/GIPR Dual Peptide Agonist varies significantly depending on the drug molecule type, process complexity, equipment scale, and production mode. Industry gross margins typically range from 60% to 80%.

Global key GLP-1/GIPR Dual Peptide Agonist players cover Eli Lilly, Roche, Viking Therapeutics, Ascletis Pharma, Jiangsu Hengrui Medicine, etc.

Key Questions Addressed in this Report

What is the 10-year outlook for the global GLP-1/GIPR Dual Peptide Agonist market?

What factors are driving GLP-1/GIPR Dual Peptide Agonist market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do GLP-1/GIPR Dual Peptide Agonist market opportunities vary by end market size?

How does GLP-1/GIPR Dual Peptide Agonist break out by Type, by Application?

This report presents a comprehensive overview of the global GLP-1/GIPR Dual Peptide Agonist market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• Injection
• Oral Administration

Segment by Receptor Agonist Properties

• Balanced
• Biased

Segment by Medicinal Efficacy

• Long-acting
• Short-acting

Segment by Application

• Diabetes
• Obesity
• Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global GLP-1/GIPR Dual Peptide Agonist market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Diabetes, Obesity, Others evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact